Medicines Company gains anti-infectives in $140m Rempex buy
This article was originally published in Scrip
The Medicines Company (MDCO) added a Phase III-ready drug candidate and other anti-infective programs to its pipeline via the acquisition of privately-held, San Diego-based Rempex Pharmaceuticals for $140m up front and up to $334m in milestone payments.
You may also be interested in...
Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.
The Medicines Co. is a few years behind its most recent beta-lactamase inhibitor competitors, but its antibiotic Carbavance is the only one with pivotal data that show superiority to a well-known drug in the same class for the treatment of hospital-based urinary tract infections.
Bristol became a major hematology player through its acquisition of Celgene and it has a multi-pronged plan for maintaining its position as generics approach for Revlimid and other key products.